BTA 243

Drug Profile

BTA 243

Alternative Names: CL 316243

Latest Information Update: 21 Mar 2002

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wyeth
  • Class Benzene derivatives; Dicarboxylic acids
  • Mechanism of Action Beta 3 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Obesity; Overactive bladder; Type 2 diabetes mellitus

Most Recent Events

  • 21 Mar 2002 Discontinued - Preclinical for Overactive bladder in USA (unspecified route)
  • 20 Mar 2002 American Home Products and its subsidiary Wyeth-Ayerst are both now called Wyeth
  • 05 Oct 2001 Preclinical development for Overactive bladder in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top